DNAnexus Completes $68 Million Financing 

February 6 2019 — MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- DNAnexus, Inc., the leader in biomedical informatics and data management, today announced closing a $68 million financing. The funds were raised from existing investors, GV (formerly Google Ventures), Foresite Capital, TPG Biotech, WuXi NextCODE, and Claremont Creek Ventures, as well as debt and equity financing from Innovatus Capital Partners, LLC.

“DNAnexus has changed how global biomedical research and development markets manage their data and infrastructures,” commented Claes Ekstrom, Managing Director at Innovatus. “We are excited to support DNAnexus’ ongoing mission to accelerate science and medical discoveries by democratizing access to data through a global network.”

The financing supports the deployment of DNAnexus Apollo ™, an advanced platform for multi-omics and clinical data exploration, analysis, and discovery. The Apollo Platform uses the DNAnexus global network, providing secure and compliant infrastructure with access to tools and datasets within a collaborative environment. DNAnexus supports some of the largest human genome sequencing projects in the world, including NIH’s St. Jude CloudAstraZeneca’s 2-million genome initiative, and the Regeneron-Geisinger collaboration.

“The financing enables further development of our translational research solutions, as well as continued growth in genomics with cloud-based solutions for research, clinical diagnostics, and clinical trials,” said Richard Daly, Chief Executive Officer at DNAnexus. “The next wave of biomedical insights will be derived from cross-institutional collaborations that generate massive volumes of clinical and multi-omics data. We are proud of our work dedicated to improving how global research and development organizations leverage large biomedical datasets to develop and deliver precision medicine solutions.”

About DNAnexus

DNAnexus, the leader in biomedical informatics and data management, has created the global network for genomics and other biomedical data, operating in 33 countries including North America, Europe, China, Australia, South America, and Africa. The secure, scalable, and collaborative DNAnexus Platform helps thousands of researchers across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia – accelerate their genomics programs. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.


About Innovatus Capital Partners

Innovatus Capital Partners, LLC, is an independent adviser and portfolio management firm with ~$1.9B in assets under management. The firm adheres to an investment strategy that identifies distressed, disruptive and growth opportunities in the less obvious market segments across multiple asset categories. Through deep industry networks and experience across asset classes, Innovatus will acquire or create assets with a focus on premium and durable income streams. Innovatus will invest through various channels including joint ventures and/or partnerships with industry-leading companies, the creation of de novo entities, and investments in or acquisitions of established companies. A unifying theme of Innovatus’ investment strategy is capital preservation and income generation. More information about Innovatus Capital Partners can be found at www.innovatuscp.com.


Jonathan Keehner / Julie Oakes / Kate Clark
Joele Frank, Wilkinson Brimmer Katcher